Login to Your Account



Ruiyi, Ihuman GPCR partnership exploits 'classic Chinese scale'

By Marie Powers
Staff Writer

Wednesday, June 18, 2014

Ruiyi Inc. and the Ihuman Institute forged a research collaboration allowing the upstart educational institution, housed at China's Shanghaitech University, to apply the company's intermembranous conformation antigen presenting system, or iCAPS, technology for the creation of monoclonal antibodies (MAb) that specifically bind to G protein-coupled receptors (GPCR). The goal of the program is to investigate the biological function and structure of GPCRs.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription